The outlook for internet stocks is rosier now that worst-case scenarios of U.S. tariffs on China appear to have been avoided.

Trump wants to replace Jerome Powell with a Fed chair who will do what he wants. But that still may not produce the steep ...

Why are people so anti-condos? It’s another way into ownership. Sure, you have to pay HOA fees, and you’re sharing walls. But ...

Semiconductor supplier Ambiq Micro on Monday said it plans to sell 3.4 million shares at between $22 and $25 apiece in its initial public offering.

Alimentation Couche-Tard will launch a share repurchase program to buy back up to 10% of its issued and outstanding shares over the course of a one-year period. The Canadian convenience store operator ...

MGP Ingredients has named food and drink industry veteran, Julie Francis, as president and chief executive. The spirits and food ingredient solutions company, which at the same time affirmed its ...

The Japanese yen is putting in a strong performance Monday morning after an election for the country's upper house dealt a big blow to the country's ruling coalition and left Prime Minister Shigeru ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Dentsply Sirona released preliminary financial results for the second quarter that would have it coming in at or above Wall Street projections. The maker of professional dental products and technology ...

Charlotte, N.C.-based Dentsply, which makes professional dental products and technology, on Monday named Scavilla as its next president and CEO, effective Aug. 1. He succeeds Simon Campion, who is ...

Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

Shares of Bruker fell after the company reported preliminary second-quarter results that missed Wall Street's expectations, hurt by what it called weak academic demand and a soft biopharma market in ...